Last updated on April 24, 2014 at 11:39 EDT

MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020

November 10, 2011

DALLAS, November 10, 2011 /PRNewswire/ –

The report “Lung Cancer Drugs Market in G7 Countries (2005 – 2020) [


]” analyzes and studies the major market drivers, restraints, and
opportunities in North America, and Europe.

Browse in-depth TOC on Lung Cancer Drugs Market in G7 Countries (2005 -

Get Free 10% customization on reports


Lung cancer is the most common form of cancer in terms of incidence and
number of deaths. It is a disease wherein the cell lining of lung tissue
grows uncontrollably and leads to the formation of tumor. There are two main
types of lung cancer; small cell lung cancer that accounts for about 20% and
non-small cell lung cancer (NSCLC) that accounts for about 80% of the total
lung cancers.

The lung cancer drugs market was valued at around $4 billion in 2010 and
is expected to reach about $13 billion by 2020, growing at a CAGR of 13.5%
from 2015 to 2020. The market was dominated by drugs such as Avastin,
Iressa, Gemzar, and Tarceva in 2010. However, by 2020, the market is
expected to be dominated by talactoferrin (Agennix), an immunomodulatory
drug; followed by Xalkori (Pfizer), and by ARQ 197 (ArQule/Daiichi Sankyo).

According to WHO, lung cancer prevalence is expected to grow in the
emerging markets such as the BRIC countries and other Asian and African
markets due to an increase in the use of tobacco products. Tobacco is the
primary cause of around 80% of all lung cancers. The other causes such as
radon gas exposure, asbestos can be causative factor for developing lung

The U.S. dominates the lung cancer drug market in North America with
93.5% share; whereas Germany dominates the market of Europe with 32.4%

Major players in the market include F. Hoffmann-La Roche Ltd
(Switzerland), AstraZeneca Plc (U.K.), Eli Lilly and Company (U.S.),
Sanofi-Aventis (France), Pfizer Inc. (U.S.), GlaxoSmithKline Pharmaceuticals
Limited (U.K.), ArQule Inc. (U.S.), Daiichi Sankyo Co. Ltd. (Japan), Agennix
AG (Germany), and Boehringer Ingelheim GmbH (Germany).

Other Reports by MarketsandMarkets

        - Diagnostic Imaging Market @


        - Healthcare IT Market @


        - Diabetes Care Devices Market @


        - US Biopharmaceutical Industry @


        - Stem Cell Technologies Market @


Upcoming Market Research by MarketsandMarkets

        - Ultrasound Market @


        - Medical Equipments Market @


        - CT Scan Market @


        - Wound Care Market @


        - Electronic Medical Records (EMR) Market @


About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company
based in the U.S. We publish strategically analyzed market research reports
and serve as a business intelligence partner to Fortune 500 companies across
the world.

MarketsandMarkets also provides multi-client reports, company profiles,
databases, and custom research services. MarketsandMarkets covers thirteen
industry verticals; including advanced materials, automotives and
transportation, banking and financial services, biotechnology, chemicals,
consumer goods, energy and power, food and beverages, industrial automation,
medical, pharmaceuticals market
[http://www.marketsandmarkets.com/pharmaceutical-market-research-3.html ],
semiconductor and electronics, and telecommunications and IT.

We at MarketsandMarkets are inspired to help our clients grow by
providing apt business insight with our huge market intelligence repository.
To know more about us and our reports, please visit our website


        Mr. Rohan
        7557 Rambler Road,
        Suite 727, Dallas, TX 75231
        Tel: +1-888-6006-441
        Email:  sales@marketsandmarkets.com
        MarketsandMarkets Blog @  http://www.marketsandmarketsblog.com


SOURCE MarketsandMarkets

Source: PR Newswire